Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127949) titled 'Prospective study on the evaluation of residual viable tumors after immune targeted conversion therapy for liver cancer using contrast-enhanced ultrasound' on July 10.
Study Type: Observational study
Study Design:
Diagnostic test for accuracy
Primary Sponsor: The First Medical Center, Chinese PLA General Hospital
Condition:
Liver carcinoma
Intervention:
Resiudual viable tumor:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-07-10
Target Sample Size: Resiudual viable tumor:81;No resiudual viable tumor:60;
Countries of Recruitment:
China
To know more, visit https://...